KLK6 and Alzheimer disease: The levels of other proteins in the CSF have also shown promise as potential biomarkers for neurodegenerative disease progression, with the levels of neurogranin (a post-synaptic marker) and kallikrein-related peptidase-6 (KLK-6) levels correlating with AD severity and advanced age respectively20–23.